Natasha F Sabur1, Mantaj S Brar2, Lisa Wu3, Sarah K Brode4. 1. Department of Respirology, St. Michael's Hospital and West Park Healthcare Centre, Rm 6-049, 30 Bond St, Toronto, ON, M5B 1W8, Canada. natasha.sabur@westpark.org. 2. Department of Surgery, University of Toronto, Toronto, Canada. 3. West Park Healthcare Centre, Toronto, Canada. 4. Department of Respirology, Toronto Western Hospital, West Park Healthcare Centre, and University of Toronto, Toronto, Canada.
Abstract
BACKGROUND: The World Health Organization recommends intravenous amikacin for the treatment of MDR-TB at a dose of 15 mg/kg. However, higher doses are associated with significant toxicity. METHODS: Patients with MDR-TB treated at our institution receive amikacin at 8-10 mg/kg, with dose adjustment based on therapeutic drug monitoring. We conducted a retrospective cohort study of patients with MDR-TB who received amikacin between 2010 and 2016. RESULTS: Forty-nine patients were included in the study. The median starting dose of amikacin was 8.9 mg/kg (IQR 8, 10), and target therapeutic drug levels were achieved at a median of 12 days (IQR 5, 26). The median duration of amikacin treatment was 7.2 months (IQR 5.7, 8), and median time to sputum culture conversion was 1 month (IQR 1,2). Six patients (12.2%) experienced hearing loss based on formal audiometry testing (95% CI 4.6-24.8%); 22.2% had subjective hearing loss (95% CI 11.2-37.1%) and 31.9% subjective tinnitus (95% CI 19.1-47.1%). Ten patients (23%) had a significant rise in serum creatinine (95% CI 11.8-38.6%), but only 5 patients had a GFR < 60 at treatment completion. 84% of patients had a successful treatment outcome (95% CI 84-99%). CONCLUSIONS: Low dose amikacin is associated with relatively low rates of aminoglycoside-related adverse events. We hypothesize that low-dose amikacin can be used as a safe and effective treatment for MDR-TB in situations where an adequate regimen cannot be constructed with Group A and B drugs, and where careful monitoring for adverse events is feasible.
BACKGROUND: The World Health Organization recommends intravenous amikacin for the treatment of MDR-TB at a dose of 15 mg/kg. However, higher doses are associated with significant toxicity. METHODS:Patients with MDR-TB treated at our institution receive amikacin at 8-10 mg/kg, with dose adjustment based on therapeutic drug monitoring. We conducted a retrospective cohort study of patients with MDR-TB who received amikacin between 2010 and 2016. RESULTS: Forty-nine patients were included in the study. The median starting dose of amikacin was 8.9 mg/kg (IQR 8, 10), and target therapeutic drug levels were achieved at a median of 12 days (IQR 5, 26). The median duration of amikacin treatment was 7.2 months (IQR 5.7, 8), and median time to sputum culture conversion was 1 month (IQR 1,2). Six patients (12.2%) experienced hearing loss based on formal audiometry testing (95% CI 4.6-24.8%); 22.2% had subjective hearing loss (95% CI 11.2-37.1%) and 31.9% subjective tinnitus (95% CI 19.1-47.1%). Ten patients (23%) had a significant rise in serum creatinine (95% CI 11.8-38.6%), but only 5 patients had a GFR < 60 at treatment completion. 84% of patients had a successful treatment outcome (95% CI 84-99%). CONCLUSIONS: Low dose amikacin is associated with relatively low rates of aminoglycoside-related adverse events. We hypothesize that low-dose amikacin can be used as a safe and effective treatment for MDR-TB in situations where an adequate regimen cannot be constructed with Group A and B drugs, and where careful monitoring for adverse events is feasible.
Entities:
Keywords:
Aminoglycosides; Hearing loss; Pharmacodynamics; Pharmacokinetics; Therapeutic drug monitoring; Tuberculosis
Authors: J A Dijkstra; T van der Laan; O W Akkerman; M S Bolhuis; W C M de Lange; J G W Kosterink; T S van der Werf; J W C Alffenaar; D van Soolingen Journal: Antimicrob Agents Chemother Date: 2018-02-23 Impact factor: 5.191
Authors: S S Shin; A D Pasechnikov; I Y Gelmanova; G G Peremitin; A K Strelis; S Mishustin; A Barnashov; Y Karpeichik; Y G Andreev; V T Golubchikova; T P Tonkel; G V Yanova; A Yedilbayev; M L Rich; J S Mukherjee; J J Furin; S Atwood; P E Farmer; S Keshavjee Journal: Int J Tuberc Lung Dis Date: 2007-12 Impact factor: 2.373
Authors: Nafees Ahmad; Shama D Ahuja; Onno W Akkerman; Jan-Willem C Alffenaar; Laura F Anderson; Parvaneh Baghaei; Didi Bang; Pennan M Barry; Mayara L Bastos; Digamber Behera; Andrea Benedetti; Gregory P Bisson; Martin J Boeree; Maryline Bonnet; Sarah K Brode; James C M Brust; Ying Cai; Eric Caumes; J Peter Cegielski; Rosella Centis; Pei-Chun Chan; Edward D Chan; Kwok-Chiu Chang; Macarthur Charles; Andra Cirule; Margareth Pretti Dalcolmo; Lia D'Ambrosio; Gerard de Vries; Keertan Dheda; Aliasgar Esmail; Jennifer Flood; Gregory J Fox; Mathilde Fréchet-Jachym; Geisa Fregona; Regina Gayoso; Medea Gegia; Maria Tarcela Gler; Sue Gu; Lorenzo Guglielmetti; Timothy H Holtz; Jennifer Hughes; Petros Isaakidis; Leah Jarlsberg; Russell R Kempker; Salmaan Keshavjee; Faiz Ahmad Khan; Maia Kipiani; Serena P Koenig; Won-Jung Koh; Afranio Kritski; Liga Kuksa; Charlotte L Kvasnovsky; Nakwon Kwak; Zhiyi Lan; Christoph Lange; Rafael Laniado-Laborín; Myungsun Lee; Vaira Leimane; Chi-Chiu Leung; Eric Chung-Ching Leung; Pei Zhi Li; Phil Lowenthal; Ethel L Maciel; Suzanne M Marks; Sundari Mase; Lawrence Mbuagbaw; Giovanni B Migliori; Vladimir Milanov; Ann C Miller; Carole D Mitnick; Chawangwa Modongo; Erika Mohr; Ignacio Monedero; Payam Nahid; Norbert Ndjeka; Max R O'Donnell; Nesri Padayatchi; Domingo Palmero; Jean William Pape; Laura J Podewils; Ian Reynolds; Vija Riekstina; Jérôme Robert; Maria Rodriguez; Barbara Seaworth; Kwonjune J Seung; Kathryn Schnippel; Tae Sun Shim; Rupak Singla; Sarah E Smith; Giovanni Sotgiu; Ganzaya Sukhbaatar; Payam Tabarsi; Simon Tiberi; Anete Trajman; Lisa Trieu; Zarir F Udwadia; Tjip S van der Werf; Nicolas Veziris; Piret Viiklepp; Stalz Charles Vilbrun; Kathleen Walsh; Janice Westenhouse; Wing-Wai Yew; Jae-Joon Yim; Nicola M Zetola; Matteo Zignol; Dick Menzies Journal: Lancet Date: 2018-09-08 Impact factor: 79.321
Authors: C Santré; H Georges; J M Jacquier; O Leroy; C Beuscart; D Buguin; G Beaucaire Journal: Antimicrob Agents Chemother Date: 1995-01 Impact factor: 5.191
Authors: Charles A Peloquin; Shaun E Berning; Annette T Nitta; Patricia M Simone; Marian Goble; Gwen A Huitt; Michael D Iseman; James L Cook; Douglas Curran-Everett Journal: Clin Infect Dis Date: 2004-05-05 Impact factor: 9.079
Authors: Chawangwa Modongo; Rafal S Sobota; Boikobo Kesenogile; Ronald Ncube; Giorgio Sirugo; Scott M Williams; Nicola M Zetola Journal: BMC Infect Dis Date: 2014-10-09 Impact factor: 3.090